Philips to acquire cardio systems
developer Witt Biomed
Fla. – Royal Philips Electronics and Witt Biomedical Corporation
announced that Philips will acquire Witt Biomedical Corporation, the
largest independent supplier of hemodynamic monitoring and clinical
reporting systems used in cardiology catheterization laboratories.
Subject to regulatory approval, Philips will acquire Witt Biomedical for
approximately US$165 million. The transaction is expected to close in
the second quarter of 2006.
In hospital Cath Labs, heart patients undergo a catheterization
procedure, in which a small tube or catheter is inserted in an artery in
the arm or leg to reach the heart for diagnosis and treatment. With the
growing digitization of hospitals, cardiologists are increasingly
demanding that Cath Labs be fully integrated into a hospital’s IT
Hemodynamic monitors measure and monitor a patient’s ECG
(electrocardiogram), blood pressure and other vital signs associated
with a Cath Lab procedure. Clinical reporting systems record and
document the entire Cath Lab procedure.
Through this acquisition, both companies expect to benefit from being
able to offer customers an integrated suite of best-in-class
technologies for the Cath Lab department, leading to increased activity
in cardiovascular x-ray, cardiology picture archiving and communication
systems (PACS), and in hemodynamic monitoring and reporting systems.
Based on company estimates, Philips in 2005 held the number one global
position in cardiovascular x-ray and in cardiology PACS. In hemodynamic
monitoring and clinical reporting systems, Witt Biomedical was the
largest independent supplier in the United States in 2005, and was the
number 2 supplier in the global market.
According to Witt Biomedical, the company’s unaudited results for 2005
were sales of approximately US$49 million –- representing a growth in
sales of 18% over 2004, and an operating margin of 30%.
Philips expects the acquisition of Witt Biomedical to be margin
accretive from 2008 onwards, with initial margin dilution due to
purchase accounting treatment. Upon completion of the acquisition, Witt
Biomedical will be integrated into the Cardiovascular X-ray business
unit within Philips’ Medical Systems Division.
“In 2005, the vendor reviewer KLAS ranked Witt Biomedical number 1 in
the Hemodynamics and Clinical Reporting market,” said Jouko Karvinen,
CEO of Philips Medical Systems. “By merging Witt Biomedical with
Philips’ successful number one position in the cardiovascular X-ray and
cardiovascular PACS markets, we intend to obtain a leading position in
the growing market for fully integrated Cath Labs,” Mr. Karvinen added.
In commenting on the acquisition, Terence Witt, founder and CEO of Witt
Biomedical said: “In the healthcare industry, Philips is known for its
high quality medical equipment and for putting customers first -– an
approach we fully share. And with Philips’ global reach, there’s clearly
an opportunity for Witt Biomedical to further build on our presence
beyond our base in North America.” Mr. Witt added: “We believe this deal
makes sense for our current and future customers, as we combine our
respective strengths in cardiology.”
To find out more about Witt Biomedical and its activities, please visit:
To find out more about Philips Medical Systems, please visit;